Report : Europe Next-generation Antibody Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapeutic Area (Oncology, and Autoimmune or Inflammatory) and Technology (Antibody-drug conjugates, Bispecific antibodies, Fc engineered antibodies, Antibody fragments & antibody-like proteins, and Biosimilar antibody products)
The oncology segment by therapeutic area is estimated to lead the market growth during the forecast period.
According to a new market research study of “Europe Next-generation Antibody Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Therapeutic Area, Technology and Country.” The Europe next-generation antibody market is expected to reach US$ 3,162.30 million by 2028 from US$ 1,455.32 million in 2021. It is estimated to grow at a CAGR of 11.7% from 2021 to 2028. The report highlights trends prevailing in the Europe mobile next-generation antibody market and the factors driving market along with those that act as hindrances.
Rising developments in biotechnology have led to increasing acceptance for next-generation antibodies therapeutics, which is further driving its use in autoimmune, inflammatory, and chronic treatment diseases. Next-generation antibody treatments have resulted from the application of sophisticated technologies in antibody therapeutics, such as antibody-drug conjugates (ADCs), glycoengineered antibodies, and specific antibodies (BsAbs). Therefore, applications of next-generation antibodies are being widely studied to treat various chronic diseases.
The rising demand for these antibodies has resulted in a rapid increase in the approval of ADCs and other next-generation antibodies therapeutics. For instance, in May 2020, Takeda Pharmaceutical Company Limited announced the FDA approval of ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ALUNBRIG's current indication has been expanded to encompass the first-line setting with its approval. It is a next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular abnormalities.
Similarly, in 2019, Genentech announced FDA accelerated approval of Polatuzumab vedotin-piiq, a CD79b-directed antibody-drug conjugate indicated in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Moreover, rising investments in next-generation antibodies from biopharmaceutical and pharmaceutical companies to manufacture and develop these next-generation antibodies are driving the market. In addition, contract manufacturing and development organizations (CDMOs) forge a link to next-generation antibody conjugates to offer even more comprehensive ADC capabilities. CDMOs are developing site-specific linker technologies, expanding their payload options, and planning for indications other than cancer. For instance, in September 2020, MilliporeSigma has announced a US$ 65 million expansion of its highly potent active pharmaceutical ingredient (HPAPI) and active pharmaceutical ingredient production capabilities and capacity at its Madison (WI) location.
Similarly, in July 2019, REGENXBIO and Neurimmune AG have signed a licensing, development, and commercialization collaboration to develop innovative AV gene treatments, employing NAV vectors to deliver human antibodies against chronic neurodegenerative disorders, such as tauopathies.
Therefore, the next-generation antibody market is anticipated to proliferate in the forecast period due to the rising clinical trials approvals and high adoption of next-generation antibody therapeutics to treat various diseases.
The European economy is severely affected due to the exponential growth of COVID-19 cases. Spain, Italy, Germany, France, and the UK are among the most affected European countries, and the number of deaths is also high. Several companies experienced severe losses in the last quarter of 2019. They also negatively influenced the first and second quarters of 2020. Hence, the impact of COVID-19 on the European market was immediate and drastic. The next-generation antibody supply chain, which is already logistically complicated, faced new challenges. The next-generation antibody market has also witnessed some shortfall at the beginning of the COVID-19 crisis due to disruption in supply chain and demand due to lockdown announced by most European countries. However, the requirement for next-generation antibodies is expected to increase due to supportive government initiatives over the next few years.
Based on therapeutic area, the Europe next-generation antibody market has been segmented into oncology and autoimmune or inflammatory. Based on application, the Europe market is segmented into antibody-drug conjugates, bispecific antibodies, Fc engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products. Geographically, the North America next-generation antibody market is sub-segmented into Germany, UK, France, Italy, Spain and Rest of Europe.
F. HOFFMANN-LA ROCHE LTD., Seagen Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Pfizer Inc., Catalent Inc and AstraZeneca are among the leading companies operating in the Europe next-generation antibody market.
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org